Standards & guidance

This FSRH Guidance provides key information and good practice points for health professionals on drug-drug interactions (DDIs) between HIV antiretroviral therapy (ART) and contraception to facilitate the prescription of safe and effective contraception to people living with HIV and on ART.

FSRH CEU new product review: Drovelis® estetrol/drospirenone combined oral contraceptive (October 2022).

Read and download the new FSRH Service Standard for Sexual Reproductive Healthcare, published in October 2022.

Read and download the new FSRH Service Standard on Obtaining Valid Consent, published in October 2022.

Read and download the new FSRH Service Standards for Clinical Risk Management in SRH, published in October 2022.

A new study (Edelman 2022) adds to the evidence around use of LNG-EC by those with higher weight/BMI but does not give a clear enough picture to inform any change in guidance.

A recently-published literature review considers the evidence around mechanism of action of levonorgestrel oral emergency contraception (LNG-EC). The findings support current FSRH guidance on emergency contraception, and are reassuring for those with ethical concerns about post-ovulation effects.

This FSRH Guidance provides evidence-based recommendations and good practice points for health professionals on drug Interaction with Hormonal Contraception. It is intended for use by health professionals working in sexual and reproductive health, general practice, and obstetric and gynaecology settings.

This FSRH Satement notes the availability and dispensive of the combined vaginal contraceptive rings in the UK.

This statement relates to a field safety notice released by intrauterine device manufacturer Eurogine in 2018 and 2019.